Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence.

Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA.

Sci Rep. 2016 Oct 31;6:36216. doi: 10.1038/srep36216.

2.

Possible basis for the emergence of H1N1 viruses with pandemic potential from avian hosts.

Koçer ZA, Krauss S, Zanin M, Danner A, Gulati S, Jones JC, Friedman K, Graham A, Forrest H, Seiler J, Air GM, Webster RG.

Emerg Microbes Infect. 2015 Jul;4(7):e40. doi: 10.1038/emi.2015.40. Epub 2015 Jul 1.

3.

Influenza virus antigenicity and broadly neutralizing epitopes.

Air GM.

Curr Opin Virol. 2015 Apr;11:113-21. doi: 10.1016/j.coviro.2015.03.006. Epub 2015 Apr 4. Review.

4.

Editorial overview: virus-glycan interactions and pathogenesis.

Venkataram Prasad BV, Air GM.

Curr Opin Virol. 2014 Aug;7:v-vi. doi: 10.1016/j.coviro.2014.07.009. Epub 2014 Aug 14. No abstract available.

5.

Influenza virus-glycan interactions.

Air GM.

Curr Opin Virol. 2014 Aug;7:128-33. doi: 10.1016/j.coviro.2014.06.004. Epub 2014 Jul 24. Review.

6.

Glycan array analysis of influenza H1N1 binding and release.

Gulati S, Lasanajak Y, Smith DF, Cummings RD, Air GM.

Cancer Biomark. 2014 Jan 1;14(1):43-53. doi: 10.3233/CBM-130376.

7.

Human H3N2 Influenza Viruses Isolated from 1968 To 2012 Show Varying Preference for Receptor Substructures with No Apparent Consequences for Disease or Spread.

Gulati S, Smith DF, Cummings RD, Couch RB, Griesemer SB, St George K, Webster RG, Air GM.

PLoS One. 2013 Jun 21;8(6):e66325. doi: 10.1371/journal.pone.0066325. Print 2013.

8.

Quantitative comparison of human parainfluenza virus hemagglutinin-neuraminidase receptor binding and receptor cleavage.

Tappert MM, Porterfield JZ, Mehta-D'Souza P, Gulati S, Air GM.

J Virol. 2013 Aug;87(16):8962-70. doi: 10.1128/JVI.00739-13. Epub 2013 Jun 5.

9.

Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.

Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, Halpert MM, Air GM.

PLoS One. 2012;7(12):e50830. doi: 10.1371/journal.pone.0050830. Epub 2012 Dec 11.

10.

Functional glycomic analysis of human milk glycans reveals the presence of virus receptors and embryonic stem cell biomarkers.

Yu Y, Mishra S, Song X, Lasanajak Y, Bradley KC, Tappert MM, Air GM, Steinhauer DA, Halder S, Cotmore S, Tattersall P, Agbandje-McKenna M, Cummings RD, Smith DF.

J Biol Chem. 2012 Dec 28;287(53):44784-99. doi: 10.1074/jbc.M112.425819. Epub 2012 Oct 31.

11.

Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.

Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, Air GM.

PLoS One. 2012;7(7):e41895. doi: 10.1371/journal.pone.0041895. Epub 2012 Jul 25.

12.

Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity.

Li Y, Silamkoti A, Kolavi G, Mou L, Gulati S, Air GM, Brouillette WJ.

Bioorg Med Chem. 2012 Jul 15;20(14):4582-9. doi: 10.1016/j.bmc.2012.05.001. Epub 2012 May 17.

13.

Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6.

Venkatramani L, Johnson ES, Kolavi G, Air GM, Brouillette WJ, Mooers BH.

BMC Struct Biol. 2012 May 6;12:7. doi: 10.1186/1472-6807-12-7.

14.

Influenza virus sequence feature variant type analysis: evidence of a role for NS1 in influenza virus host range restriction.

Noronha JM, Liu M, Squires RB, Pickett BE, Hale BG, Air GM, Galloway SE, Takimoto T, Schmolke M, Hunt V, Klem E, García-Sastre A, McGee M, Scheuermann RH.

J Virol. 2012 May;86(10):5857-66. doi: 10.1128/JVI.06901-11. Epub 2012 Mar 7.

15.

Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus.

Vista ES, Crowe SR, Thompson LF, Air GM, Robertson JM, Guthridge JM, James JA.

Lupus. 2012 Feb;21(2):168-74. doi: 10.1177/0961203311429554.

16.

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.

Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.

Retrovirology. 2011 Dec 7;8:101. doi: 10.1186/1742-4690-8-101.

17.

Influenza neuraminidase.

Air GM.

Influenza Other Respir Viruses. 2012 Jul;6(4):245-56. doi: 10.1111/j.1750-2659.2011.00304.x. Epub 2011 Nov 16. Review.

18.

Fixation of oligosaccharides to a surface may increase the susceptibility to human parainfluenza virus 1, 2, or 3 hemagglutinin-neuraminidase.

Tappert MM, Smith DF, Air GM.

J Virol. 2011 Dec;85(23):12146-59. doi: 10.1128/JVI.05537-11. Epub 2011 Sep 14.

19.

A sialylated glycan microarray reveals novel interactions of modified sialic acids with proteins and viruses.

Song X, Yu H, Chen X, Lasanajak Y, Tappert MM, Air GM, Tiwari VK, Cao H, Chokhawala HA, Zheng H, Cummings RD, Smith DF.

J Biol Chem. 2011 Sep 9;286(36):31610-22. doi: 10.1074/jbc.M111.274217. Epub 2011 Jul 12.

20.

Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.

Air GM, Feng J, Chen T, Joachims ML, James JA, Thompson LF.

J Clin Immunol. 2011 Oct;31(5):900-12. doi: 10.1007/s10875-011-9563-1. Epub 2011 Jul 6.

21.

Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Crowe SR, Merrill JT, Vista ES, Dedeke AB, Thompson DM, Stewart S, Guthridge JM, Niewold TB, Franek BS, Air GM, Thompson LF, James JA.

Arthritis Rheum. 2011 Aug;63(8):2396-406. doi: 10.1002/art.30388.

22.

Antibody quantity versus quality after influenza vaccination.

Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, James JA, Thompson LF, Air GM.

Vaccine. 2009 Oct 23;27(45):6358-62. doi: 10.1016/j.vaccine.2009.06.090.

23.
24.

HLA class I molecules consistently present internal influenza epitopes.

Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):540-5. doi: 10.1073/pnas.0811271106. Epub 2009 Jan 2.

25.

Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.

Gulati U, Keitel WA, Air GM.

Influenza Other Respir Viruses. 2007 Jul;1(4):147-56. doi: 10.1111/j.1750-2659.2007.00017.x.

26.

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC.

Nature. 2008 May 29;453(7195):667-71. doi: 10.1038/nature06890. Epub 2008 Apr 30.

27.

Evolving complexities of influenza virus and its receptors.

Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS.

Trends Microbiol. 2008 Apr;16(4):149-57. doi: 10.1016/j.tim.2008.01.008. Epub 2008 Mar 28. Review.

PMID:
18375125
29.

Receptor binding specificity of recent human H3N2 influenza viruses.

Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM.

Virol J. 2007 May 9;4:42.

30.

An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.

Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, Bochkarev A, Air GM.

J Mol Biol. 2006 Feb 24;356(3):651-63. Epub 2005 Dec 7.

PMID:
16384583
31.

Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5.

Lee JT, Air GM.

Virology. 2006 Feb 20;345(2):424-33. Epub 2005 Nov 16.

32.

Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses.

Gulati U, Wu W, Gulati S, Kumari K, Waner JL, Air GM.

Virology. 2005 Aug 15;339(1):12-20.

33.
34.

Binding of influenza viruses to sialic acids: reassortant viruses with A/NWS/33 hemagglutinin bind to alpha2,8-linked sialic acid.

Wu W, Air GM.

Virology. 2004 Aug 1;325(2):340-50. Erratum in: Virology. 2004 Nov 10;329(1):213-4.

35.

A benzoic acid inhibitor induces a novel conformational change in the active site of Influenza B virus neuraminidase.

Lommer BS, Ali SM, Bajpai SN, Brouillette WJ, Air GM, Luo M.

Acta Crystallogr D Biol Crystallogr. 2004 Jun;60(Pt 6):1017-23. Epub 2004 May 21.

PMID:
15159560
36.

Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.

Brouillette WJ, Bajpai SN, Ali SM, Velu SE, Atigadda VR, Lommer BS, Finley JB, Luo M, Air GM.

Bioorg Med Chem. 2003 Jul 3;11(13):2739-49.

PMID:
12788348
37.

Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).

Gulati U, Hwang CC, Venkatramani L, Gulati S, Stray SJ, Lee JT, Laver WG, Bochkarev A, Zlotnick A, Air GM.

J Virol. 2002 Dec;76(23):12274-80.

38.
39.
40.

Influenza virus infection of desialylated cells.

Stray SJ, Cummings RD, Air GM.

Glycobiology. 2000 Jul;10(7):649-58.

PMID:
10910970
41.

Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.

Atigadda VR, Brouillette WJ, Duarte F, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck E, Finley J, Air GM, Luo M, Laver GW.

Bioorg Med Chem. 1999 Nov;7(11):2487-97.

PMID:
10632058
42.
43.

Influenza neuraminidase as target for antivirals.

Air GM, Ghate AA, Stray SJ.

Adv Virus Res. 1999;54:375-402. Review. No abstract available.

PMID:
10547680
44.

Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.

Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M.

J Mol Biol. 1999 Nov 12;293(5):1107-19.

PMID:
10547289
45.

Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.

Brouillette WJ, Atigadda VR, Luo M, Air GM, Babu YS, Bantia S.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1901-6.

PMID:
10450950
46.

Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.

Atigadda VR, Brouillette WJ, Duarte F, Ali SM, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck EA, Finley J, Luo M, Air GM, Laver GW.

J Med Chem. 1999 Jul 1;42(13):2332-43.

PMID:
10395473
47.
48.
49.

Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM, Walsh GM.

Antimicrob Agents Chemother. 1998 Apr;42(4):801-7.

50.

Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.

Colacino JM, Laver WG, Air GM.

J Infect Dis. 1997 Aug;176 Suppl 1:S66-8.

PMID:
9240698

Supplemental Content

Support Center